Last reviewed · How we verify
TJ0113
At a glance
| Generic name | TJ0113 |
|---|---|
| Sponsor | Hangzhou PhecdaMed Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Single Ascending Dose Study(SAD),Multiple Ascending Dose Study(MAD) , High-fat Diet Study (FE) of TJ0113 Capsules in Healthy Subjects (PHASE1)
- Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder (PHASE2)
- Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease (PHASE2)
- Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects (PHASE1)
- A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TJ0113 CI brief — competitive landscape report
- TJ0113 updates RSS · CI watch RSS
- Hangzhou PhecdaMed Co., Ltd. portfolio CI